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BACKGROUND: The vascular disrupting agent combretastatin A4 phosphate (CA4P) causes major regression of animal tumours when
given as combination therapy.
METHODS: Patients with advanced cancer refractory to standard therapy were treated with CA4P as a 10-min infusion, 20h before
carboplatin, paclitaxel, or paclitaxel, followed by carboplatin.
RESULTS: Combretastatin A4 phosphate was escalated from 36 to 54mgm
 2 with the carboplatin area under the concentration
curve (AUC) 4–5, from 27 to 54mgm
 2 with paclitaxel 135–175mgm
 2, and from 54 to 72mgm
 2 with carboplatin AUC 5
and paclitaxel 175mgm
 2. Grade 3 or 4 neutropenia was seen in 17%, and thrombocytopenia only in 4% of 46 patients. Grade 1–3
hypertension (26% of patients) and grade 1–3 tumour pain (65% of patients) were the most typical non-haematological toxicities.
Dose-limiting toxicity of grade 3 hypertension or grade 3 ataxia was seen in two patients at 72mgm
 2. Responses were seen in 10 of
46 (22%) patients with ovarian, oesophageal, small-cell lung cancer, and melanoma.
CONCLUSION: The combination of CA4P with carboplatin and paclitaxel was well tolerated in the majority of patients with adequate
premedication and had antitumour activity in patients who were heavily pretreated.
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Tumour vascular disrupting agents (VDAs) are a new class of
cancer therapies that target the existing vasculature of tumours
to cause rapid vascular shutdown in the tumour, leading to cell
death (Patterson and Rustin, 2007). Combretastatin A4 Phosphate
(CA4P) is a tubulin-binding VDA that displays potent and selective
toxicity towards tumour vasculature (Tozer et al, 1999). After
single-agent administration in preclinical models, rapid regrowth
of the viable tumour rim is observed, which obtains its nutrients
from the surrounding normal tissue and blood supply (Salmon
and Siemann, 2007). However, when CA4P is combined with a
variety of cytotoxic agents, as well as with radiotherapy and
antiangiogenesis inhibitors, enhanced tumour control is achieved
in vivo (Grosios et al, 2000; Murata et al, 2001; Siemann et al, 2002;
Staflin et al, 2006; Yeung et al, 2007).
Four phase 1 trials of CA4P have demonstrated minimal single-
agent antitumour activity, and have confirmed that it has vascular
disrupting activity according to functional imaging (Dowlati et al,
2002; Stevenson et al, 2003; Rustin et al, 2003a; Cooney et al,
2006). Dose-limiting toxicities (DLTs) were seen at doses above
50mgm
 2. In view of the enhanced activity observed when
CA4P is combined with cisplatin (El Zayat et al, 1993), carboplatin
(Landuyt et al, 2000), CPT11 (Wildiers et al, 2004), or paclitaxel
(Yeung et al, 2007) in vivo, human combination studies are the
next step.
A phase I trial of carboplatin (dose to produce an area under
the concentration curve (AUC) 4 or 5), followed 1h later by CA4P
27–36mgm
 2, demonstrated grade 3 or 4 thrombocytopenia in
9 of 16 (56%) patients in any course (Bilenker et al, 2005).
Decreased renal perfusion was likely the cause of reduced
carboplatin clearance and subsequent increase in myelotoxicity
(Anderson et al, 2003). This suggests that when administering
CA4P in combination with carboplatin, the reduction in renal
perfusion induced by CA4P needs to have recovered before
administering carboplatin. Administering carboplatin/paclitaxel
24h after CA4P has been shown to be as effective as administering
it before CA4P in MDA MB-231 breast adenocarcinoma xenografts
(Edvardsen and Chaplin, personal communication). There is
evidence that 24h after CA4P administration, there is both
continued proliferation of the viable tumour rim and revascular-
isation, the latter stimulated at least in part by circulating endo-
thelial progenitor cells (Shaked et al, 2006). This might therefore
be the best time to administer carboplatin. In clinical practice,
carboplatin is frequently given in combination with paclitaxel for
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slung and ovarian cancer. As this combination showed enhanced
activity when administered with CA4P in the KAT-4 model (nude
mice bearing human anaplastic thyroid cancer xenografts) (Yeung
et al, 2007) and as better therapies are needed for these cancers,
a clinical trial was indicated. In view of the toxicity observed
by Bilenker et al (2005), we planned a dose-escalation and
pharmacokinetic study initially combining CA4P with carboplatin
or paclitaxel as doublets before combining all three drugs.
MATERIALS AND METHODS
Patient selection
Patients with histologically confirmed cancer, not amenable to
standard therapy or refractory to conventional therapy, were
eligible for this study. Other eligibility requirements included
ECOG performance status 0–2; life expectancy X4 months; age
X18 years; adequate bone marrow function (granulocyte count
41500cellsmm
 3; platelet count 4100000cellsmm
 3); adequate
hepatic function (total bilirubin o1.5mg per 100ml; ALT and
AST o2.5  upper limit of normal); adequate renal function with
glomerular filtration rate (GFR) measured by EDTA clearance
450mlmin
 1; no other anticancer therapy for 4 weeks; no active
concurrent malignancies except cone-biopsied in situ carcinoma
of the cervix, or adequately treated basal or squamous carcinoma
of skin.
Patients were excluded if they had brain metastases, serious
infection or other non-malignant illness, Xgrade 2 neuropathy,
major surgery within 4 weeks, previously administered radical
radiotherapy or evidence of vascular damage from radiotherapy,
history of peripheral vascular disease, history of angina, myo-
cardial infarction, arrhythmias, or conditions associated with QTc
prolongation, uncontrolled hypertension, or anticoagulation apart
from low-dose warfarin for maintenance of central line patency.
Study design
This was a three-centre, open-label dose-escalation study to
initially assess the safety and tolerability of combining CA4P at
doses ranging from 36 to 60mgm
 2, with carboplatin doses from
AUC 4 to 5, and of combining CA4P at doses from 27 to 54mgm
 2
with paclitaxel doses from 135 to 175mgm
 2. The next stage was
combining CA4P with both carboplatin and paclitaxel. The actual
dose-escalation scheme achieved is shown in the results section
(Table 1). The study was approved by participating hospitals
ethical review boards, and all enrolled patients provided written
informed consent.
Treatment and dose escalation
On day 1 of each 21-day cycle, patients received a 10-min infusion
of CA4P. Routine premedication was not mandated but if toxicity
occurred with the first course, premedication with dexamethasone
and metaclopramide was suggested for future courses. On day 2,
18–22h after administering CA4P, patients received a 60-min
infusion of carboplatin or a 3-h infusion of paclitaxel. Glomerular
filtration rate was measured by EDTA clearance. The dose of
carboplatin corresponded to a target AUC and was calculated
using a modified Calvert formula:
Carboplatinðdose per cycle in mgÞ¼ð target AUCÞ ðGFR þ 25Þ:
Provided no DLT occurred in any of the three patients
per cohort, doses were increased as shown in Table 1. Once it
had been ascertained that no DLTs were observed at a CA4P dose
of 54mgm
 2 in either of the doublets, patients were then treated
with the triplet of drugs at doses shown in Table 1. If a DLT was
observed, three additional patients could be recruited to that dose
level. The triplet consisted of CA4P on day 1, followed 18–22h
later by a 3-h infusion of paclitaxel, then a 60-min infusion of
carboplatin. A dose-modification schedule based on grade X2
neurological or cardiac toxicity and grade 3 or 4 other toxicities
was adhered to.
Dose-limiting toxicity was defined as any of the following
occurring in the first cycle: QTc prolongation X500ms, 4grade 2
ventricular arrhythmia, grade 3 or 4 non-haematological toxicity
(except fatigue/asthenia, nausea and/or vomiting), toxicity result-
ing in a treatment delay of 414 days, absolute granulocyte count
o500cellsmm
 3 for 45 consecutive days or febrile neutropenia
with granulocyte count o1000cellsmm
 3, thrombocytopenia
o25000cellsmm
 3 or bleeding episode requiring platelet trans-
fusion, grade X2 neuropathy, which does not recover to grade 1
within 14 days after scheduled retreatment, or any grade toxicity
requiring patient removal from the study on the basis of the
judgement of investigators.
The maximum tolerated dose was defined as the maximum dose
level of CA4P, administered in combination with carboplatin and
paclitaxel, at which one or fewer patients experience a DLT.
Treatment assessment
Laboratory assessments (including full blood counts) were
performed weekly. Tumour evaluations were carried out at
screening and then every two cycles. Criteria for response were
based on Response Evaluation Criteria in Solid Tumours (RECIST)
(Therasse et al, 2000) and response according to CA-125 was based
on definitions agreed by the Gynaecologic Cancer Intergroup
(Rustin, 2003).
Pharmacokinetics
The plasma pharmacokinetics (PK) of carboplatin and paclitaxel
were evaluated during cycle 1 in all patients receiving study
treatment. For carboplatin and paclitaxel PK, blood samples
were collected 20h after CA4P infusion, on starting the
60-min carboplatin infusion and/or the 3-h paclitaxel infusion,
respectively.
Table 1 Dose-escalation scheme: treatment cohorts with number of patients treated and courses given
Trial arms
Arm 1: CA4P/Carboplatin Arm 2: CA4P/Paclitaxel Arm 3: CA4P/Carboplatin/Paclitaxel
Cohort 1 2 3 4 5 12345 1 2 3
CA4P dose (mgm
 2) 3 64 54 56 05 42 72 7 3 6 4 5 5 4 5 4 6 3 7 2
Carboplatin AUC 4 4 5 5 5 — — — — — 5 5 5
Paclitaxel dose (mgm
 2) — — — — — 135 175 175 175 175 175 175 175
Number of patients 3 3 3 1 5 4 3345 4 6 2
Total number of cycles 14 8 11 1 21 16 11 10 11 20 23 27 6
Abbreviations: AUC¼area under the concentration curve; CA4P¼combretastatin A4 phosphate.
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sPlasma concentration data for paclitaxel and carboplatin
plasma ultrafiltrate concentrations were analysed using non-
compartmental methods. Peak concentrations (Cmax) were deter-
mined manually. The terminal elimination rate constants (lz)
were determined by linear regression analysis of the terminal
log-linear part of the concentration–time curve. The total area
under the observed plasma concentration–time curve (AUC) was
calculated for each analyte from time zero to the last measured
concentration, using the linear-log trapezoid rule. Area under the
concentration curve values were extrapolated from the last
observed time point to infinity by adding the last measured
concentration divided by lz.
Statistical analysis
Non-parametric tests were used to calculate the statistical signi-
ficance of differences between several groups (the Kruskal–Wallis
test), and between two groups for paired (Wilcoxon signed rank-
sum test) and unpaired (the Mann–Whitney U-test) data, and
of correlations (Spearman).
RESULTS
Patients and dose escalation
Between 27 June 2003 and 1 November 2005, 46 patients with a
median age of 58 years were enrolled. Patient characteristics are
listed in Table 2.
The dose-escalation schedule and the number of patients treated
in each cohort are shown in Table 1. A total of 180 cycles were
given to 46 patients, with 15 patients completing all 6 cycles. In all,
17 patients withdrew because of tumour progression, three because
of early death (all due to tumour progression), five because of
toxicity (two patients with grade 3 fatigue, one patient with grade 2
sensory neuropathy, one patient with a grade 4 allergic reaction to
carboplatin, and one patient with grade 3 neutropenia and flu-like
symptoms), and six for other reasons (one patient needed surgery
for small-bowel obstruction, one patient experienced a clonic
seizure, one patient was unwilling to continue, two patients had no
clear clinical benefit, and the investigator decided to withdraw one
patient). Of 180 cycles, 15 (8%) had to be delayed, mostly because
of haematological toxicity.
Haematological toxicity
The worst grade of haematological toxicity for each patient at
each dose level is shown in Table 3. Despite blood counts being
performed weekly, grade 3 or 4 thrombocytopenia was only seen
in two patients: one in the paclitaxel doublet arm and one in
the triplet arm. Grade 3 and 4 neutropenia was only seen in
eight patients, all of them in the triplet arm.
Non-haematological toxicity
Worst drug-related toxicities are summarised in Table 4. Overall,
pain was one of the commonest toxicities and almost invariably
an exacerbation of preexisting (tumour) pain, typically starting
within 1h of the commencement of the CA4P infusion and
lasting up to a few hours, affecting 30 out of 46 patients (65%). No
patient stopped treatment because of pain, as it was controllable
with analgesia that included morphine. Neuropathy (paraesthesia)
was more common in the paclitaxel (53%) and triplet (67%) arms,
but there were still 47% of patients in the CA4P/carboplatin arm
experiencing paraesthesia grade 1–3.
Rare but important non-haematological toxicities included
allergic and neurological reactions. One patient experienced a
non-fatal anaphylactic shock (common terminology criteria for
adverse events (CTCAE) grade 4) as an allergic reaction to
carboplatin. Short-lived and spontaneously resolving muscle
weakness of the legs and arms (CTCAE grade 3 and 2) was
observed in two patients, although the second patient’s symptoms
Table 2 Patient characteristics (n¼46)
Characteristics No. of patients
Assessable for response 46
Gender
Male 18
Female 28
Age, years
Median 57
Range 24–77
WHO performance status
01 3
12 9
24
Prior therapy
Chemotherapy 44
Radiotherapy 7
Hormonal or biological therapy 13
Tumour type
Ovary 16
Melanoma 6
Colorectal 5
Kidney 5
Lung 3
Oesophagus 2
Thyroid 2
Gastrointestinal stroma tumour 1
Neuroendocrine tumour 1
Cholangiocarcinoma 1
Leiomyosarcoma of the uterus 1
Testis 1
Primary peritoneal carcinoma 1
Fallopian tube 1
Abbreviation: WHO¼World Health Organization.
Table 3 Worst haematological toxicity per patient (all cycles)
Number of patients
Carboplatin arm Paclitaxel arm Triplet arm
CTCAE grade 1
Anaemia 7 9 5
Lymphopenia 3 2 2
Neutropenia 2 — —
Thrombocytopenia 4 2 7
CTCAE grade 2
Anaemia 6 5 6
Lymphopenia — — —
Neutropenia 2 6 2
Thrombocytopenia 1 — —
CTCAE grade 3–4
Anaemia — 1 1
Lymphopenia 2 3 1
Neutropenia — — 8
Thrombocytopenia — 1 1
Abbreviation: CTCAE¼common terminology criteria for adverse events.
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was only diagnosed later.
Ataxia was seen in two patients (CTCAE grade 2 and 3) and
resolved spontaneously within a couple of hours. CTCAE grade 3
ataxia occurred 1 day after the first CA4P infusion in one patient
and was considered DLT.
Short-lived and spontaneously resolving dysphasia was observed
in two patients treated in trial arm 1 at a CA4P dose of 54mgm
 2.
One patient was unable to speak for 1min, 2h after his second
CA4P infusion (initially deemed CTCAE grade 1 by the local
investigator, amended to grade 2 upon monitoring as there is
no grade 1 for such an event according to CTCAE Version 3.0),
and a second patient experienced dysphasia the day after the
first infusion of CA4P, lasting less than 5min. This event was
initially deemed grade 2 by the local investigator, but amended
to grade 3 later by the principal investigator, and was therefore not
captured as a DLT at the time; both patients continued on the trial.
Cardiac toxicity
In all, 12 of the 46 patients (26%) experienced hypertension, most
were CTCAE grade 1 (Table 4). Dose-limiting toxicity of grade 3
hypertension, which was asymptomatic, was seen in one patient at
72mgm
 2 CA4P. In general, both systolic and diastolic blood
pressures were highest at 1h, followed by slight hypotension 4h
after CA4P infusion (Figure 1A). Changes in both systolic and
diastolic blood pressures correlate significantly with the CA4P
dose during the first cycle (Figure 1B, data shown for systolic
blood pressure only). Ten patients were already on antihyper-
tensive medication at study inclusion. Eight of these patients
showed at least one episode of hypertension during the study. For
comparison, only 4 of the 36 patients not taking antihypertensive
medication developed at least one episode of hypertension during
the study. Only four patients needed treatment for hypertension
related to study medication, of whom two were already on
antihypertensive medication. Study guidelines initially advised
hydralazine and clonidine to be given when systolic blood pressure
exceeded 180mmHg, but this was later amended to glyceryl
trinitrate (GTN). Only the last patient in the study experienced
hypertension who needed treatment with GTN sublingually
(Figure 1C).
Table 4 Worst non-haematological drug-related toxicity per patients
(all cycles)
Treatment arm
Number of patients
Carboplatin
arm
Paclitaxel
arm
Triplet
arm
CTCAE grade Toxicity 1 2 3 1 2 3 1 2 3
Fatigue 4 5 3 5 7 — 3 5 —
Pain 6 4 2 2 8 2 1 5 0
Sensory neuropathy 6 — 1 8 1 1 5 3 —
Alopecia — — — 2 12 — 1 7 —
Nausea 4 5 — 4 2 — 3 4 —
Pain – headache 1 5 1 3 1 — 1 4 —
QTc prolongation 3 — — 7 2 — 2 1 —
Vomiting 3 2 1 3 3 — — 2 —
Hypertension 3 2 — 1 2 — 3 — 1
Constipation — 4 — 1 4 — — 2 —
Diarrhoea 2 1 3 1 1 — 2 3
Pyrexia 3 — — 5 2 — 1 — —
Flushing 3 1 — 1 — — 2 1 —
Hypotension — 1 — 1 3 — 1 2 —
Itching 3 — — 1 — — 4 — —
Anorexia 1 1 — — — — 4 1 —
Infection — 1 — — 1 2 2 1 —
Myalgia 1 — — 3 — — 2 1 —
Neurological: muzzy head 2 — — 2 — — 1 — —
Oedema 2 1 — 1 1 — — — —
Perianal itching 3 — — 1 — — 1 — —
Rash — 1 — 1 1 2 — — —
Stomatitis 1 — — 1 1 — 2 — —
Tachycardia 1 — — 2 — — 2 — —
Agitation 2 — 1 1 — — — — —
Cough — 1 — 1 — 1 — — —
Motor neuropathy — 1 1 — — 1 — — —
Allergy — — 1
a —— 1 1— —
Ataxia — — — — — — — 1 1
Dysphasia — 1 1 — — — — — —
Dehydration — — — — — 1 — — —
Incontinence — — 1 — — — — — —
Sepsis — — 1 — — — — — —
Abbreviation: CTCAE¼common terminology criteria for adverse events.
aGrade 4
toxicity.
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Figure 1 (A) Systolic and diastolic blood pressure (mean±s.d.) before and every hour for 6h after combretastatin A4 phosphate (CA4P) infusion in all
46 patients during the first cycle. *Po0.05 vs pretreatment measurement. n¼46 patients. (B) Relationship between CA4P dose (mgm
 2) and systolic
blood pressure changes (in percent) 1h after CA4P infusion during the first cycle with fitted regression line. n¼46 patients. (C) Blood pressure changes in a
patient with hypertension after CA4P, responding to 0.3mg sublingual glyceryl trinitrate.
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mostly CTCAE grade 1, and in three patients with grade 2, the
longest interval being 480ms. Patients from all three treatment
arms were affected. Two of the patients with QTc prolongations
were on antihypertensive medication at study entry. Grade 1
tachycardia was seen in 11% of patients. No cardiac enzyme
measurements were taken as none of the patients had clinical
symptoms of myocardial ischemia. The only patient with a known
history of ischemic heart disease did not experience hypertension
or QTc prolongation.
Pharmacokinetics
Complete plasma data were available for 12 patients for estimation
of PK variables for carboplatin (Table 5), and for 31 patients for
estimation of PK variables for paclitaxel. Pharmacokinetics could
not be estimated for all patients because of sampling problems.
The differences between calculated and measured carboplatin AUC
did not differ significantly between the different CA4P dose
groups, or for the group also receiving paclitaxel, indicating no
pharmacological interaction between these drugs using this
regimen. Table 5 also shows nadir blood counts demonstrating
no relationship with measured carboplatin AUC. A total of
27 patients who received paclitaxel 175mgm
 2 had the AUC of
paclitaxel measured, which varied from 463 to 4709mgminml
 1,
with no significant relationship to the dose of CA4P, indicating no
interaction between these drugs using this regimen (data not
shown).
Response
Patients with ovarian cancer Seven of 18 (39%) patients with
epithelial ovarian cancer, primary peritoneal carcinoma, or cancer
of the fallopian tube had a response according to RECIST and/or
GCIG CA-125 criteria. Of them, one had a confirmed and two had
an unconfirmed partial remission (PR) according to RECIST, and
a response according to GCIG CA-125 criteria, and four had a
response according to GCIG CA-125 criteria only.
Patients with non-ovarian cancer Three of 30 (10%) patients
with non-ovarian cancer showed PR according to RECIST: one in
trial arm 2 with extensive small-cell lung cancer, progressing
to 2 months after previous response to carboplatin, etoposide,
and thalidomide within a phase III trial; another in trial arm 2
with an adenocarcinoma of the oesophagus–gastric junction, for
relapse after surgical resection and adjuvant epirubicin/cisplatin/
capectabine, followed by second-line mitomycin C chemotherapy;
and a third in trial arm 3 with metastatic melanoma of the skin
progressing during first-line trial therapy with dacarbazine and
sorafenib.
DISCUSSION
This phase Ib trial was planned because of the severe myelo-
suppression observed when combining CA4P with carboplatin in
a previous study and the concerns about combining the two
different tubulin-binding agents, combretastatin A4 phosphate
and paclitaxel. It was the concern about the possibility of
CA4P enhancing haematological and neurotoxicity that led us to
perform this trial rather than performing a phase II trial with
a cohort of patients treated with a lower dose of CA4P, as was
the approach followed in the trial of another VDA, DMXAA
(Rustin et al, 2003b).
However, this trial has shown that it is safe to combine doses
of CA4P that have been shown to reduce tumour blood flow
(Anderson et al, 2003; Galbraith et al, 2003; Stevenson et al, 2003)
with doses of carboplatin and paclitaxel that are considered
standard therapy. In a previous study, CA4P 27–36mgm
 2 was
given 1h after carboplatin AUC 4 or 5, resulting in 56% (9 of 16) of
patients suffering grade 3 or 4 thrombocytopenia (Bilenker et al,
2005). In this study, grade 3 or 4 thrombocytopenia was seen only
in 4% of patients with similar doses of carboplatin but with doses
of CA4P up to 72mgm
 2. Administering carboplatin at least
20h after CA4P has dramatically reduced myelosuppression.
The degree of grade 3 or 4 myelosuppression with the triplet
was lower than that observed previously without CA4P (Vasey
et al, 2004).
As ataxia and motor neuropathy were DLTs in the first phase I
trial of CA4P at 114mgm
 2 (Rustin et al, 2003a), the starting dose
when combined with the neurotoxic drug paclitaxel was reduced
to 27mgm
 2. In this study, neurotoxicity was seen in the form of
sensory neuropathy in 54% of patients, mostly of CTCAE grade 1
(41% of patients) and probably more related to paclitaxel than to
CA4P. Motor neuropathy, ataxia, and dysphasia were observed in
a total of six patients (13%) at doses between 45 and 72mgm
 2
CA4P and were of short duration, lasting a couple of minutes to
a few hours.
Patients who already took medication to control arterial hyper-
tension at the time of study entry were more likely to experience
hypertension after CA4P infusion. One patient received GTN for
the treatment of CTCAE grade 1 hypertension, which proved to be
highly effective in quickly normalising blood pressure, but we now
recommend giving GTN as a dermal patch to reduce the side
effects of sublingual GTN. The notion that nitrates and calcium
channel blockers such as amlodipine are highly effective has
Table 5 Carboplatin pharmacokinetics and blood count nadirs
Patient
no.
Carboplatin
AUC
calculated
CA4P
dose
(mgm
 2)
Paclitaxel
dose
(mgm
 2)
Carboplatin
AUC measured
(mgminml
 1)
Carboplatin
Cmax
(ngml
 1)
Haemoglobin
nadir
(g per 100ml)
Neutrophil
nadir
( 10
3ll
 1)
Platelet
nadir
( 10
3ll
 1)
10 4 45 — 4.03 24700 12.7 2.31 203
12 4 45 — 4.08 24800 8.5 5.40 302
13 4 45 — 8.66 105000 12.0 2.26 147
14 5 45 — 5.79 41100 11.0 2.72 103
15 5 45 — 5.55 31900 8.6 3.32 175
17 5 45 — 5.24 41300 10.0 3.31 165
21 5 54 — 6.71 31200 10.1 2.85 106
23 5 54 — 5.38 33200 10.6 2.51 215
32 5 54 — 4.60 21000 10.1 1.78 172
34 5 54 — 3.27 11500 12.4 1.60 196
39 5 63 175 3.98 15700 9.7 0.63 323
41 5 63 175 3.85 21100 10.5 0.68 137
Abbreviations: AUC¼area under the concentration curve; CA4P¼combretastatin A4 phosphate.
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There remains a concern that hypertension induced by CA4P could
cause myocardial or cerebral damage, especially as many elderly
patients with cancer have preexisting cardiovascular disease. As we
previously demonstrated that CA4P efficiency is dose dependent
(Rustin et al, 2003a), and have evidence from this study that
hypertension also follows a dose-dependent pattern, we have
introduced the prophylactic use of amlodipine in current protocols
for the ongoing clinical development of combretastatin A1
phosphate.
Pharmacokinetics showed no evidence of pharmacological
interaction between carboplatin or paclitaxel and CA4P. Dose-
limiting toxicities were CTCAE grade 3 ataxia and CTCAE grade 3
arterial hypertension at 72mgm
 2 CA4P. Thus, the recommended
dose for phase II trials is 63mgm
 2 CA4P, combined with carbo-
platin AUC 5 (based on GFR measured by EDTA clearance), and
paclitaxel 175mgm
 2.
It is encouraging that responses were observed in a variety
of tumour types, including ovarian cancer (7 of 18 patients
responding), small-cell lung cancer, adenocarcinoma of the
oesophagus–gastric junction, and malignant melanoma (three
patients with PR), demonstrating response in a total of 22% of all
patients (including two patients with unconfirmed response). The
high response rate in ovarian cancer demonstrates further
evidence that this disease is responsive to vascular strategies,
and in consequence, a phase II trial in platinum-resistant ovarian
cancer has been completed.
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